Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer

Bente Vilming, Jørgen Fallås Dahl, Anne Gry Bentzen, Vibeke Anett Ingebrigtsen, Elisabeth Berge Nilsen, Ingvild Vistad, Anne Dørum, Olesya Solheim, Line Bjørge, Manuela Zucknick, Guro Aune, Kristina Lindemann · 2023

Read Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer by Bente Vilming, Jørgen Fallås Dahl, Anne Gry Bentzen, Vibeke Anett Ingebrigtsen, Elisabeth Berge Nilsen, Ingvild Vistad, Anne Dørum, Olesya Solheim, Line Bjørge, Manuela Zucknick, Guro Aune, Kristina Lindemann (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10803952.txt.

Description

Bente Vilming and eleven colleagues published a 2023 real-world study of niraparib, a maintenance drug for recurrent ovarian cancer. Patients whose cancer responded to platinum chemotherapy can take niraparib to delay its return. Most trial evidence comes from patients with inherited BRCA mutations; this study covers those without them.

The retrospective cohort included 94 patients with platinum-sensitive recurrent ovarian cancer and no known germline BRCA1 or BRCA2 mutation, treated through an individual access program in Norway. The main outcome was the time from starting niraparib to the start of the next treatment, a practical measure of benefit. Real-world data of this kind shows how a drug performs outside the strict conditions of trials.

Catalog record

CREATORBente Vilming, Jørgen Fallås Dahl, Anne Gry Bentzen, Vibeke Anett Ingebrigtsen, Elisabeth Berge Nilsen, Ingvild Vistad, Anne Dørum, Olesya Solheim, Line Bjørge, Manuela Zucknick, Guro Aune, Kristina Lindemann
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE28 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10803952

Browse the full library · About the Tower of Babel